ideas that fuel dialogue
when to talk to your healthcare team about biomarker testing
because not all tumours behave the same way, biomarkers can provide information about the molecular characteristics of a tumour creating a personalized approach to treating cancer. knowing your biomarker status can determine if targeted therapies are right for you and...
why precision medicine matters
when we talk about mutations, this represents a very small amount of cancer patients - in colorectal cancer for example, mutations in NTRK, MSI-h/dMMR, and BRAF are considered rare [1%, 15%, 9% respectively]. however, this actually represents respectively-...
colorectal cancer canada survey results on molecular profiling in canada
@coloncanada through their GET PERSONAL program launched a two phase project- the first phase of the project included a The first phase of the project included a pan-tumour, pan-canadian survey that was sent to multi-disciplinary healthcare professionals aimed to...
the importance of biomarker testing
over the last two weeks we’ve shared lots of information about biomarkers and targeted therapies - but what does it all really mean? we wanted to show how important molecular profiling/biomarker testing is to guide treatment planning for patients. these graphics are...
let’s talk about biomarkers – BRAF
BRAF represents one of the most frequently mutated protein kinase genes in human tumours. BRAF mutation is seen in melanoma, papillary thyroid carcinoma [including papillary thyroid carcinoma arising from ovarian teratoma], ovarian serous tumours, colorectal...
let’s talk about biomarker – NTRK
neurotrophic tyrosine receptor kinase [NTRK] oncogenic NTRK gene fusions occur in many different tumour types. while present in a majority of certain rare tumours, such as secretory carcinoma of the breast or salivary gland and infantile fibrosarcoma, they are also...
we can be the catalyst for change.
fostering an environment of co-creation & collaboration to make action-oriented changes in cancer care in canada.